GGrantIndex
Sort

261,768 grants matching gene therapy

Mechanism, Regulation and Application of miRNA pathway in cancer

$1,200,709
Shuo Gu · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1

$1,200,531
Xiaodong Cheng · University Of Texas Hlth Sci Ctr Houston · R01 · FY2018 · AI

Dynamic State Space Modeling of Cancer Cell Response to Therapy

$1,200,478
Garry P Nolan · University Of Southern California · U54 · FY2010 · CA

Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease

$1,200,379
David A Williams · Boston Children'S Hospital · OT2 · FY2020 · HL

Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma

$1,200,301
Douglas F Nixon · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · CA

Gene Therapy Resource Program Pharmacology-Toxicology Core Lab

$1,200,000
Fraser Wright · Lovelace Biomedical & Environmental Research Institute · N01 · FY2014 · HL

Collaborative Research: MODULUS: Uncovering and re-engineering chromatin modification circuits that dictate epigenetic cell memory

$1,200,000
Domitilla Del Vecchio · Massachusetts Institute Of Technology · · FY2020 · BIO

CER on CAM Antioxidant Therapies (CERCAT)

$1,200,000
Balz B Frei · Oregon State University · P01 · FY2008 · AT

CER on CAM Antioxidant Therapies (CERCAT)

$1,200,000
Balz B Frei · Oregon State University · P01 · FY2010 · AT

Cellular and molecular mediators of fibrosis in the development of urinary tract dysfunction

$1,200,000
William Ricke · University Of Wisconsin-Madison · U54 · FY2019 · DK

CER on CAM Antioxidant Therapies (CERCAT)

$1,200,000
Balz B Frei · Oregon State University · P01 · FY2009 · AT

Center for Herbal Research on Colorectal Cancer

$1,199,999
Chun-Su Yuan · University Of Chicago · P01 · FY2009 · AT

Novel Small-Molecule Inhibitors of Bcl-2/Bcl-xL Protein*

$1,199,944
University Of Michigan At Ann Arbor · U19 · FY2005 · CA

Signal Transduction Events and the Regulation of Cell Growth

$1,199,893
Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2021 · CA

New statistical methods for neutral phylogenetic reconstruction

$1,199,723
Volodymyr M Minin · University Of Washington · · FY2009 · MPS

SBIR Phase II: Preclinical Validation of an Ocular Antioxidant Enhancing Gene Delivery Vehicle for Dry Macular Degeneration

$1,199,722
Ramaswamy L Ramkumar · Oculogenex · · FY2022 · TIP

Novel Molecular Therapies of Prostate Cancer

$1,199,386
Dario C. Altieri · Wistar Institute · P01 · FY2011 · CA

PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate BiomarkersTask Order Title: Sulforaphane for the Prevention of Malignant Mesothelioma

$1,199,274
Joseph Testa · Research Inst Of Fox Chase Can Ctr · N01 · FY2023 · CA

Signaling in the retina and retinal pigment epithelium

$1,199,202
Thomas Redmond · National Eye Institute · ZIA · FY2020 · EY

FORMULATION OF RATIONAL THERAPY OF NEPHROLITHIASIS

$1,199,141
University Of Texas Sw Med Ctr/Dallas · P01 · FY2003 · DK

FORMULATION OF RATIONAL THERAPY OF NEPHROLITHIASIS

$1,199,141
University Of Texas Sw Med Ctr/Dallas · P01 · FY2002 · DK

Oral Microbial and Immunological Characterization of Patients with Immune Dysfun

$1,199,034
Niki Moutsopoulos · National Institute Of Dental & Craniofacial Research · ZIA · FY2018 · DE

Gene Therapy for Metabolic Disorders

$1,198,865
Chester B Whitley · University Of Minnesota · P01 · FY2014 · HD

Gene Therapy for Metabolic Disorders

$1,198,672
Chester B Whitley · University Of Minnesota · P01 · FY2016 · HD

Lymphoma Disease Discovery and Definition

$1,198,546
Elaine Jaffe · Division Of Clinical Sciences - Nci · ZIA · FY2024 · CA